Drug Approval | March 17, 2022
Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
According to the Indian Council of Medical Research (ICMR), there will be an estimated 12 % rise in cancer cases in India in the next five years
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Clinical surveillance solution is designed to identify emergent patient deterioration and offer enhanced patient data visibility, flexible viewing options, and clinical decision support
Machine learning approach to systems biology combined with ligand discovery platform
Onco Care Plus is available at just INR 399 per month, and provides services like free doctor consultation, 15% off on cancer treatment costs, 25% off for diagnostic tests, free nutrition plans, among many more
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Empowers the lab to do more in less time within the existing floor plan by integrating clinical chemistry and immunoassay testing onto a single platform
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
Subscribe To Our Newsletter & Stay Updated
